Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

111
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting Complications after Radical Nephrectomy with Venous Tumor Thrombectomy and Various IVC Reconstruction Approaches: A Simplified Risk Calculator.

Urology·2026
Same author

A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder.

Urology·2026
Same author

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria.

The Prostate·2026
Same author

Salvage lymph node dissection in oligo-recurrent prostate cancer patients: Mapping patterns of recurrence and factors associated with disease progression.

Urologic oncology·2026
Same author

Evaluation of algorithms for predicting new baseline renal function after complex partial nephrectomy for multifocal renal tumors.

Urologic oncology·2026
Same author

A silver lining … in the ureter: Keratinizing squamous metaplasia with a metallic twist.

Urology case reports·2026

Related Experiment Video

Updated: Jun 14, 2025

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

482

Comparing Frailty Indices for Risk Stratification in Urologic Oncology: Which Index to Choose?

Ekamjit S Deol1, Vidit Sharma1, Anthony E Fadel1

  • 1Department of Urology, Mayo Clinic, Rochester, MN.

Urology
|August 30, 2024
PubMed
Summary

The revised Risk Analysis Index (RAI-Rev) better predicts mortality and non-home discharge after major urologic surgery compared to the modified Frailty Index (mFI). RAI-Rev shows greater utility for surgical risk stratification in these patients.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Related Experiment Videos

Last Updated: Jun 14, 2025

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles
04:00

Author Spotlight: Assessing Surgical Frailty with Point-of-Care Ultrasound of Quadriceps Muscles

Published on: July 26, 2024

482
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
05:53

Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty

Published on: July 24, 2013

16.6K

Area of Science:

  • Urologic Oncology
  • Geriatric Surgery
  • Health Services Research

Background:

  • Frailty assessment is crucial for surgical risk stratification in major urologic oncologic surgery.
  • The modified Frailty Index (mFI) and the revised Risk Analysis Index (RAI-Rev) are common frailty screening tools.
  • Identifying the optimal tool is essential for accurate perioperative outcome prediction.

Purpose of the Study:

  • To compare the predictive performance of mFI and RAI-Rev for 30-day perioperative outcomes.
  • To determine the superior frailty screening tool for surgical risk stratification in major urologic oncologic surgery.

Main Methods:

  • Analysis of 101,739 patients undergoing major urologic surgery (2013-2017) from the NSQIP database.
  • Multivariable logistic regression to assess the association of mFI and RAI-Rev with major complications, Clavien grade ≥4 complications, non-home discharge, readmission, and mortality.
  • Receiver-operating characteristic (ROC) curve analysis and DeLong's test to compare the predictive abilities (C-statistics) of the two indices.

Main Results:

  • RAI-Rev demonstrated superior discriminatory ability for mortality (C-statistic: 0.688-0.798) and non-home discharge (C-statistic: 0.638-0.734) compared to mFI (C-statistic: 0.594-0.677 and 0.593-0.639, respectively).
  • Both indices showed similar predictive performance for major perioperative complications (C-statistic: 0.531-0.607).
  • Statistically significant differences favoring RAI-Rev were confirmed for mortality and non-home discharge (P < .001).

Conclusions:

  • RAI-Rev appears to be a more effective prognostic tool than mFI for patients undergoing major urologic surgery.
  • These findings suggest RAI-Rev may offer greater utility in surgical risk stratification.
  • Future prospective studies and clinical trials should consider these comparative results in their design.